Sunshine Biopharma Files 8-K: Accountant Change & Exhibits
Ticker: SBFMW · Form: 8-K · Filed: May 6, 2024 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma, Inc (SBFMW) |
| Form Type | 8-K |
| Filed Date | May 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, exhibits, financials
Related Tickers: SBFM
TL;DR
Sunshine Biopharma changed auditors and filed exhibits on 5/3.
AI Summary
Sunshine Biopharma, Inc. filed an 8-K on May 3, 2024, reporting changes in its certifying accountant and filing financial statements and exhibits. The company, formerly known as Mountain West Business Solutions, Inc., is incorporated in Colorado and based in New York.
Why It Matters
This filing indicates a change in the company's auditor, which can sometimes signal underlying financial reporting issues or a strategic shift in how the company presents its financials.
Risk Assessment
Risk Level: medium — Changes in certifying accountants can sometimes precede or coincide with financial reporting issues or restatements.
Key Numbers
- 001-41282 — SEC File Number (Identifies the company's filing with the SEC)
- 20-5566275 — IRS Employer ID No. (Company's tax identification number)
Key Players & Entities
- Sunshine Biopharma, Inc. (company) — Registrant
- Mountain West Business Solutions, Inc. (company) — Former Company Name
- May 3, 2024 (date) — Date of earliest event reported
- 1177 Avenue of the Americas (location) — Business Address
FAQ
What is the primary reason for the change in Sunshine Biopharma's certifying accountant?
The filing does not explicitly state the reason for the change in certifying accountant, only that it is being reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 3, 2024.
What was Sunshine Biopharma, Inc. formerly known as?
Sunshine Biopharma, Inc. was formerly known as Mountain West Business Solutions, Inc.
In which state is Sunshine Biopharma, Inc. incorporated?
Sunshine Biopharma, Inc. is incorporated in Colorado.
What is the business address of Sunshine Biopharma, Inc.?
The business address is 1177 Avenue of the Americas, 5th Floor, New York, NY 10036.
Filing Stats: 747 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-05-06 12:14:14
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Filing Documents
- sunshine_8k.htm (8-K) — 29KB
- sunshine_ex1601.htm (EX-16.1) — 2KB
- image_004.jpg (GRAPHIC) — 3KB
- image_006.jpg (GRAPHIC) — 13KB
- 0001683168-24-003004.txt ( ) — 268KB
- sbfm-20240503.xsd (EX-101.SCH) — 3KB
- sbfm-20240503_def.xml (EX-101.DEF) — 26KB
- sbfm-20240503_lab.xml (EX-101.LAB) — 36KB
- sbfm-20240503_pre.xml (EX-101.PRE) — 25KB
- sunshine_8k_htm.xml (XML) — 5KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant (a) The financial statements of Sunshine Biopharma, Inc. (the "Company"), for the fiscal years ended December 31, 2023 and 2022, were audited by BF Borgers CPA, PC ("Borgers"). On May 3, 2024, the Securities and Exchange Commission (the "SEC") announced that it had settled charges against Borgers that it failed to conduct audits in accordance with the standards of the Public Company Accounting Oversight Board (the "PCAOB"). As part of the settlement, Borgers agreed to a permanent ban on appearing or practicing before the SEC. As a result of Borgers' settlement with the SEC, the Company has dismissed Borgers as its independent accountant. The decision to dismiss Borgers as the Company's independent registered public accounting firm was approved by the audit committee of the Company's board of directors. Borgers' reports on the Company's financial statements for the two most recent fiscal years did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope, or accounting principles. During the Company's two most recent fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through May 3, 2024, there were no disagreements, within the meaning of Item 304(a)(1)(iv) of Regulation S-K, with Borgers on any matter of accounting principles or practices, financial caused it to make reference to the subject matter of the disagreements in connection with its reports. Also during this same period, there were no reportable events that existed within the meaning of Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto. The Company provided Borgers with the disclosures under this Item 4.01(a), and requested Borgers to furnish the Company with a letter addressed to the SEC stating wheth
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 16.1 Letter from Borgers 104 Cover Page Interactive Data File (formatted in Inline XBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 6, 2024 SUNSHINE BIOPHARMA, INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3